Key facts
- Tumours stopped growing in 90% of the 61 trial patients, and shrank or disappeared in just over 60%.
- A year after starting daraxonrasib, 76.6% of patients were alive; 40-45% given chemotherapy alone usually survive a year.
- Patients were followed for a year and a half on average, and some saw no return of the cancer in that period.
- Daraxonrasib is a KRAS inhibitor that locks on to and shuts off mutations found in most pancreatic cancers.
- Michelle Mitchell of Cancer Research UK said more trials are needed before the treatment can be assessed for NHS use.
A pill called daraxonrasib shrank or eliminated tumours in patients with advanced pancreatic cancer in a trial whose findings were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, according to a report published on November 20, 2026.
In the trial, 61 patients recently diagnosed with advanced pancreatic cancer that had spread to other parts of the body were given the drug. Tumours stopped growing in 90% of them, just over 60% had tumours shrink or disappear, and in about 8%, or one in 12, the cancer became undetectable on CT scans. Patients were followed for a year and a half on average, and some did not see the cancer return during that period.
A year after starting treatment, 76.6% of patients were alive, against 40-45% of patients given chemotherapy alone who usually survive a year. Half of all people diagnosed with pancreatic cancer die within three months, and about 3% of patients survive five years when the disease spreads to other organs, the report said.
Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, presented the findings. "This is the closest to cure," he said, adding that he had never seen so many tumours disappear in patients whose cancer had spread. "The median follow-up is 18 months," he said. "Just imagine, in an average of 18 months your disease just disappears on the CT scan."
Daraxonrasib is a KRAS inhibitor, a treatment that works by locking on to and shutting off certain mutations found in most pancreatic cancers, which drive tumour growth. The report said there are hopes the treatment could work for dozens of other cancers that can carry similar mutations.
Michelle Mitchell, chief executive of Cancer Research UK, said more research was needed. "This is the biggest leap forward we've seen in decades for pancreatic cancer patients," she said, adding that more trials are needed before the treatment can be assessed for use on the NHS. Doctors said the pill cannot yet be considered a cure and they do not know how long it can keep the disease at bay.